Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1978 1
1980 1
1984 2
1985 1
1986 1
1988 1
1994 1
1995 1
1996 1
1997 2
1998 10
1999 18
2000 31
2001 18
2002 15
2003 32
2004 35
2005 45
2006 56
2007 54
2008 51
2009 75
2010 69
2011 72
2012 79
2013 72
2014 89
2015 93
2016 89
2017 57
2018 67
2019 77
2020 75
2021 61
2022 76
2023 72
2024 120
2025 125
2026 82

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,644 results

Results by year

Filters applied: . Clear all
Page 1
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Cardoso F, et al. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2. N Engl J Med. 2025. PMID: 40454634 Clinical Trial.
BACKGROUND: Women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention among those at high risk for breast cancer commonly have vasomotor symptoms. Data are lacking on the effects of elinzanetant, a neurokinin-targeted thera …
BACKGROUND: Women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention among those at high risk fo …
Management of Menopausal Symptoms: A Review.
Crandall CJ, Mehta JM, Manson JE. Crandall CJ, et al. JAMA. 2023 Feb 7;329(5):405-420. doi: 10.1001/jama.2022.24140. JAMA. 2023. PMID: 36749328 Review.
During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symptoms) and more than 50% have genitourinary symptoms (genitourinary syndrome of menopause [GSM]). OBSERVATIONS: Vasomoto …
During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor …
The Menopause Transition: Signs, Symptoms, and Management Options.
Santoro N, Roeca C, Peters BA, Neal-Perry G. Santoro N, et al. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1-15. doi: 10.1210/clinem/dgaa764. J Clin Endocrinol Metab. 2021. PMID: 33095879 Free article. Review.
EVIDENCE SYNTHESIS: The reproductive hormonal milieu of the menopausal transition precipitates bothersome vasomotor symptoms, mood disruption, temporary cognitive dysfunction, genitourinary symptoms, and other disease processes that reduce the quality of life …
EVIDENCE SYNTHESIS: The reproductive hormonal milieu of the menopausal transition precipitates bothersome vasomotor symptoms, …
A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial.
Barnard ND, Kahleova H, Holtz DN, Znayenko-Miller T, Sutton M, Holubkov R, Zhao X, Galandi S, Setchell KDR. Barnard ND, et al. Menopause. 2023 Jan 1;30(1):80-87. doi: 10.1097/GME.0000000000002080. Epub 2022 Oct 16. Menopause. 2023. PMID: 36253903 Free PMC article. Clinical Trial.
OBJECTIVE: Postmenopausal vasomotor symptoms disrupt quality of life. This study tested the effects of a dietary intervention on vasomotor symptoms and menopause-related quality of life. ...During a 12-week period, a mobile application was used to reco …
OBJECTIVE: Postmenopausal vasomotor symptoms disrupt quality of life. This study tested the effects of a dietary intervention …
Management of perimenopausal and menopausal symptoms.
Duralde ER, Sobel TH, Manson JE. Duralde ER, et al. BMJ. 2023 Aug 8;382:e072612. doi: 10.1136/bmj-2022-072612. BMJ. 2023. PMID: 37553173 Review.
Most women worldwide experience menopausal symptoms during the menopause transition or postmenopause. Vasomotor symptoms are most pronounced during the first four to seven years but can persist for more than a decade, and genitourinary symptoms tend to …
Most women worldwide experience menopausal symptoms during the menopause transition or postmenopause. Vasomotor symptoms …
Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages.
Deecher DC, Dorries K. Deecher DC, et al. Arch Womens Ment Health. 2007;10(6):247-57. doi: 10.1007/s00737-007-0209-5. Epub 2007 Dec 12. Arch Womens Ment Health. 2007. PMID: 18074100 Review.
Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are the menopausal symptoms for which women seek treatment during menopause most often. ...Hormone therapy is the most effective treatment for VMS and other …
Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are the menopausal s …
Menopausal Symptoms and Their Management.
Santoro N, Epperson CN, Mathews SB. Santoro N, et al. Endocrinol Metab Clin North Am. 2015 Sep;44(3):497-515. doi: 10.1016/j.ecl.2015.05.001. Endocrinol Metab Clin North Am. 2015. PMID: 26316239 Free PMC article. Review.
For postmenopausal women changes in cognition are more likely to be related to aging and not to hormones. This article reviews the symptoms of hot flashes (vasomotor symptoms), vaginal dryness/dyspareunia, adverse mood, poor sleep/insomnia, and …
For postmenopausal women changes in cognition are more likely to be related to aging and not to hormones. This article reviews the sympto …
Menopause.
Takahashi TA, Johnson KM. Takahashi TA, et al. Med Clin North Am. 2015 May;99(3):521-34. doi: 10.1016/j.mcna.2015.01.006. Med Clin North Am. 2015. PMID: 25841598 Review.
During menopause, women experience a variety of predictable symptoms and conditions related to changes in sex hormone levels and aging. The menopausal transition precedes menopause by several years and is usually characterized by irregularity of the menstrual cycle and by …
During menopause, women experience a variety of predictable symptoms and conditions related to changes in sex hormone levels and agin …
Vasomotor Symptoms Across the Menopause Transition: Differences Among Women.
Avis NE, Crawford SL, Green R. Avis NE, et al. Obstet Gynecol Clin North Am. 2018 Dec;45(4):629-640. doi: 10.1016/j.ogc.2018.07.005. Epub 2018 Oct 25. Obstet Gynecol Clin North Am. 2018. PMID: 30401547 Free PMC article. Review.
Vasomotor symptoms (VMS) are the primary menopausal symptoms, occurring in up 80% of women and peaking around the final menstrual period. ...Risk factors include greater body composition (in the early stage of menopausal transition), smoking, anxiety, depress …
Vasomotor symptoms (VMS) are the primary menopausal symptoms, occurring in up 80% of women and peaking around the final …
ACOG Practice Bulletin No. 141: management of menopausal symptoms.
[No authors listed] [No authors listed] Obstet Gynecol. 2014 Jan;123(1):202-216. doi: 10.1097/01.AOG.0000441353.20693.78. Obstet Gynecol. 2014. PMID: 24463691
Vasomotor and vaginal symptoms are cardinal symptoms of menopause. Vasomotor symptoms can be particularly troubling to women and are the most commonly reported menopausal symptoms, with a reported prevalence of 50-82% among U.S. women who …
Vasomotor and vaginal symptoms are cardinal symptoms of menopause. Vasomotor symptoms can be particularly …
1,644 results